BioStats GmbH as Your Partner for DiGA Studies
BioStats supports you from study planning to statistical reporting – with experience from numerous BfArM consultations and successfully approved applications.
To ensure that your digital health application (DiGA) can be included in the BfArM directory, its efficacy must be scientifically demonstrated. BioStats GmbH guides you through the entire process, from endpoint definition to statistical analysis, always in line with BfArM’s methodological requirements.
Our Experience in DiGA Studies
Die BioStats GmbH unterstützt Sie bei Erfüllung dieser Anforderungen und der damit zusammenhängenden Planung, Durchführung und Auswertung Ihrer klinischen Studie. Damit begleiten wir Sie zuverlässig auf dem Weg zur Aufnahme Ihrer DiGA ins Verzeichnis. Dabei profitieren Sie von unserer langjährigen Erfahrung und unserer Teilnahme an zahlreichen Beratungsgesprächen mit dem BfArM, in denen wir tiefe Einblicke in die Anforderungen gewinnen konnten.
We offer comprehensive expertise in:
• Study Planning: Development of a methodologically sound study design in line with BfArM requirements.
• Endpoints & Evidence: Support in defining clinically relevant endpoints and demonstrating the effectiveness of your DiGA.
• Minimal Important Difference (MCID): Ensuring results are not only statistically significant but also clinically meaningful.
• Sample Size Calculation: Determining the necessary number of participants to ensure robust and reliable outcomes.
• Statistical Methods: Application of advanced statistical techniques, including handling missing data and complex endpoints.
• Result Reporting: Preparation of results in tables, figures, and listings (TFLs), providing clear interpretation for regulators and stakeholders.
Our Services for Your DiGA Study
• Study protocol
• Statistical analysis plan (SAP)
• Randomization lists
• Data management
• Data evaluation
• Statistical report
• Study documentation
• Evaluation report according to §137e SGB V
We have already supported several digital health application providers that have been successfully listed and bring expertise in the following areas:
• Mental and behavioral disorders
• Endocrine, nutritional, and metabolic diseases
• Diseases of the circulatory system
• Skin and eye diseases
• Respiratory diseases
• Nervous system diseases
Why BioStats
• Experience with BfArM consultations and deep understanding of regulatory requirements
• Combination of scientific methodology and practical experience
• Proven track record: multiple digital health applications successfully included in the DiGA directory
Your Contact at BioStats
Contact us for a non-binding conversation with Dr. Alexander Krannich personally.
Frequently Asked Questions
How does BioStats GmbH support the planning of clinical studies?
We help you define clear study endpoints, select a suitable study design, and carefully plan the sample size. In this way, we ensure that your study is based on scientifically sound foundations from the very beginning.
What types of studies does BioStats GmbH have experience with?
We support a wide range of study designs, including cross-sectional studies, case-control studies, cohort studies, and randomized controlled trials (RCTs). We also have special expertise in the field of digital health applications (DiGA).
What statistical methods does BioStats GmbH use?
Our team selects the optimal statistical tests and models for your project. This also includes complex procedures such as adjustment for confounders or handling multiple tests. The goal is to achieve valid and reliable results.
What expertise does Dr. Alexander Krannich bring?
Dr. Krannich is a statistician and data scientist with many years of experience in university and industrial research. His main areas of focus include the analysis of drug studies, medical device and DiGA studies, Health Technology Assessments (HTA) and real-world data (RWD/RWE).
© 2025 BioStats GmbH. All rights reserved. | Webdesign von Philipp Kufferath